A Study to Test the Addition of the Drug Cabozantinib to Chemotherapy in Patients With Newly Diagnosed Osteosarcoma
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT05691478 |
Recruitment Status :
Suspended
(Scheduled Interim Monitoring)
First Posted : January 20, 2023
Last Update Posted : May 17, 2024
|
Sponsor:
National Cancer Institute (NCI)
Information provided by (Responsible Party):
National Cancer Institute (NCI)
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : | Suspended |
---|---|
Estimated Primary Completion Date : | March 20, 2030 |
Estimated Study Completion Date : | March 20, 2030 |